secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001867096-23-000045
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris expands board to 9, appoints Ricki Fairley as Class III director
----------------------------------------------------------------------

- Ricki Fairley appointed to board on March 27, 2023, expanding board from 8 to 9 members.
- Fairley brings 35+ years of marketing experience; currently CEO of TOUCH, The Black Breast Cancer Alliance.
- Received 85,000 RSUs vesting in equal annual installments over three years.
- Fairley's compensation follows the Non-Employee Director Compensation Policy filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000045/0001867096-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000045/xers-20230327.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer